SWitching to Abilify Trial (SWAT)

Exclusion Criteria

• •Patients who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
• •Women who are pregnant or breastfeeding
• •Patients who are at risk for committing suicide: either having active suicidal ideation considered clinically significant or recently attempted suicide
• •Patients with a diagnosis of bipolar disorder, depression with psychotic symptoms, or organic brain syndromes
• •Patients who have met DSM-IV criteria for any significant Psychoactive Substance Use Disorder within the 3 months prior to Screening
• •Patients considered treatment-resistant to antipsychotic medication (patients need to have shown a previous response to a antipsychotic medication other than clozapine) and patients with a significant history of intolerance to multiple antipsychotic treatments
• •Treatment with a long-acting antipsychotic (i.e., haloperidol decanoate or fluphenazine decanoate) in which the last dose was within 3 weeks of randomization.
• •Patients with a history of neuroleptic malignant syndrome
• •Patients with epilepsy, a history of seizures (except for a single childhood febrile seizure), or a history of an abnormal EEG, severe head trauma, or stroke or who have a history or evidence of other medical conditions (e.g., congestive heart failure) that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
• •Patients who would be likely to require prohibited concomitant therapy during the trial
• •Patients who have previously enrolled in an aripiprazole clinical study or who have participated in any clinical trial with an investigational agent within the past month
• •Prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.